Commerzbank Aktiengesellschaft FI Sells 4,143 Shares of Stryker Corporation $SYK

Commerzbank Aktiengesellschaft FI lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 15.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,137 shares of the medical technology company’s stock after selling 4,143 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Stryker were worth $8,132,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. United Financial Planning Group LLC bought a new stake in Stryker during the 3rd quarter valued at $27,000. Strive Asset Management LLC bought a new stake in Stryker during the 3rd quarter valued at $30,000. CGC Financial Services LLC bought a new stake in Stryker during the 4th quarter valued at $29,000. ANTIPODES PARTNERS Ltd bought a new stake in Stryker during the 3rd quarter valued at $34,000. Finally, Copia Wealth Management boosted its position in Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after acquiring an additional 69 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president directly owned 177 shares in the company, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.60% of the stock is owned by company insiders.

Stryker Stock Performance

Shares of SYK stock opened at $306.74 on Friday. The firm has a market capitalization of $117.59 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 1.92 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business has a fifty day moving average of $329.68 and a 200 day moving average of $351.73. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analyst Ratings Changes

Several analysts have recently commented on SYK shares. Wells Fargo & Company decreased their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a report on Friday, May 1st. Jefferies Financial Group reiterated a “buy” rating and set a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Evercore set a $355.00 price objective on Stryker in a report on Friday, May 1st. Finally, Piper Sandler reiterated an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.